AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 26938750
Drug: Sildenafil OSF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil OSF 100 mg formulations
Trial: 26938750
Drug: Sildenafil citrate
RxNorm normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sildenafil citrate 100 mg tablets
Trial: 6752963
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg diazepam suppositories
Trial: 19213575
Drug: Interscalene continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interscalene continuous infusion of 2% ropivacaine (2 mL/h)
Trial: 19213575
Drug: Subacromial continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subacromial continuous infusion of 2% ropivacaine (2 mL/h)
Trial: 15123230
Drug: Budesonide/formoterol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide/formoterol (1 inhalation)
Trial: 7720476
Drug: Ondansetron (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (0.15 mg/kg, single intravenous dose)
Trial: 2297461
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg oral loperamide (4 doses)
Trial: 2297461
Drug: 16 mg
RxNorm normalized name: escin 16 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 mg oral loperamide (1 dose)
Trial: 2297461
Drug: 16 mg
RxNorm normalized name: escin 16 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 mg oral loperamide (2 doses)
Trial: 30711321
Drug: Daily dressing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dressing
Trial: 30711321
Drug: Weekly dressing
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly dressing
Trial: 24700581
Drug: Immediate-release opioid
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release opioid (oxycodone or morphine)
Trial: 21705873
Drug: CUIDATE group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CUIDATE group (multidimensional physical therapy program)
Trial: 10233317
Drug: MPD regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MPD regimen starting with 50% of the minimal phototoxic dose (MPD) with weekly increments of 40%, 30%, 25%, 20%, 15%, 10% and 5% to a maximum of 14.5 J/cm2
Trial: 10233317
Drug: Skin type
RxNorm normalized name: CVS Skin Tag Remover For All Skin Types Homeopathic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Skin type regimen starting with a fixed dose based on skin type with weekly dose increments of 40%, decreasing to 20% once erythema develops
Trial: 10233317
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment groups (MPD and skin type regimen)
Trial: 28182820
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg Resveratrol (RSVhigh)
Trial: 28182820
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg Resveratrol
Trial: 22000728
Drug: Dialysate tCa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialysate tCa concentration of 3.0 mEq/L
Trial: 22000728
Drug: Dialysate tCa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialysate tCa concentration of 2.75 mEq/L
Trial: 22000728
Drug: Dialysate tCa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialysate tCa concentration of 2.5 mEq/L
Trial: 19199349
Drug: Axillary treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Axillary treatment (dissection or radiotherapy)
Trial: 31098832
Drug: 25 mL
RxNorm normalized name: ethanol 6.025 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mL of 6% CHO mouth rinse
Trial: 24833043
Drug: bilastine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bilastine (20 mg)
Trial: 24833043
Drug: hydroxyzine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hydroxyzine (25 mg)
Trial: 15165613
Drug: L-ornithine alpha-ketoglutarate
RxNorm normalized name: ornithine alpha-ketoglutarate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-ornithine alpha-ketoglutarate (OKG) 10 g/d for 12 weeks
Trial: 9357387
Drug: Chlorzoxazone 250
RxNorm normalized name: chlorzoxazone 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorzoxazone 250 mg
Trial: 9597564
Drug: Chlorzoxazone 750
RxNorm normalized name: chlorzoxazone 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorzoxazone 750 mg
Trial: 7905550
Drug: More-effective treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: More-effective treatments (6 or more cycles of cyclophosphamide, methotrexate, fluorouracil and prednisone; with or without tamoxifen, or tamoxifen and prednisone alone)
Trial: 7905550
Drug: Less-effective treatments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Less-effective treatments (no treatment or a single cycle of chemotherapy)
Trial: 3266449
Drug: Atropine (0.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine (0.01 mg/kg, intravenous)
Trial: 31570429
Drug: Docetaxel treatment
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel treatment in variant carriers (ANO7 rs77559646)
Trial: 28538831
Drug: Laryngeal Manual
RxNorm normalized name: LARYNGEAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laryngeal Manual Therapy (LMT)
Trial: 23379785
Drug: High-bolus-dose tirofiban
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-bolus-dose tirofiban
Trial: 21234549
Drug: AZD3783 (1-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD3783 (1-40 mg oral doses)
Trial: 18293707
Drug: Levocetirizine (LCZ)
DrugBank: Levocetirizine (DB06282)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levocetirizine (LCZ) 5 mg p.o.
Trial: 12418583
Drug: telithromycin 800
RxNorm normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: telithromycin 800 mg once daily (qd) for 5 days
Trial: 12418583
Drug: amoxicillin/clavulanate 500/125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: amoxicillin/clavulanate 500/125 mg three times daily (tid) for 10 days
Trial: 10080588
Drug: BR96‐doxorubicin conjugate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BR96‐doxorubicin conjugate 700 mg/m2 IV over 24 hours
Trial: 10080588
Drug: Doxorubicin 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin 60 mg/m2 every 3 weeks
Trial: 6998872
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg spironolactone
Trial: 3621990
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg spironolactone
Trial: 6998872
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg spironolactone
Trial: 8916244
Drug: Usual treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual treatment (control group)
Trial: 19563497
Drug: Continuous etanercept
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Continuous etanercept therapy (25 mg SC BIW throughout 54 weeks)
Trial: 19563497
Drug: Paused etanercept
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paused etanercept therapy (50 mg SC BIW for up to 12 weeks, then 25 mg BIW upon retreatment)
Trial: 20492876
Drug: Continuous etanercept
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Continuous etanercept therapy
Trial: 19563497
Drug: Paused etanercept
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paused etanercept therapy
Trial: 19563497
Drug: Both continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both continuous and paused etanercept treatment
Trial: 9298132
Drug: Urinary excretion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urinary excretion of 5-S-cysteinyldopa (5-S-CD)
Trial: 9298132
Drug: Urinary excretion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urinary excretion of 5-S-cysteinyldopa (5-S-CD) > 1,000 micrograms/day
Trial: 9298132
Drug: Urinary excretion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urinary excretion of 5-S-cysteinyldopa (5-S-CD) > 10,000 micrograms/day
Trial: 9298132
Drug: Urinary excretion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urinary excretion of 5-S-cysteinyldopa (5-S-CD) > 40,000 micrograms/day
Trial: 2873379
Drug: Atenolol (5-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (5-10 mg iv immediately, followed by 100 mg/day orally for 7 days)
Trial: 28616715
Drug: Intravitreal injection
RxNorm normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection of bevacizumab without anterior chamber paracentesis (group A)
Trial: 28616715
Drug: Intravitreal injection
RxNorm normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection of bevacizumab with anterior chamber paracentesis (group B)
Trial: 24080992
Drug: Zoledronic acid,
RxNorm normalized name: Zoledronic Acid, Anhydrous
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid, 4 mg, concurrently with the start of RT and then every six months for a total of 6 infusions (Arm 1)
Trial: 21484236
Drug: Drug-related mood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-related mood induction
Trial: 17143195
Drug: 500 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg/day RRR-alpha-tocopherol
Trial: 17143195
Drug: 500 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg/day mixed tocopherols (60% gamma-tocopherol)
Trial: 15138711
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion etoposide (days 1-6)
Trial: 15138711
Drug: Bolus infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bolus infusion etoposide (over 10 h on day 7)
Trial: 15138711
Drug: High-dose etoposide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose etoposide (schedule-dependent)
Trial: 11294082
Drug: Antidepressant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant treatment (specifics not available)
Trial: 2087150
Drug: Placebo (0.9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.9% saline, 1 ml; i.v.)
Trial: 240205
Drug: 1.25 mg
RxNorm normalized name: menthol 1.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 mg of lorazepam (orally) as a soporific and premedication
Trial: 240205
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg of lorazepam (orally) as a soporific and premedication
Trial: 31269050
Drug: Treatment (home
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment (home visits, baby massage, and parenting program)
Trial: 28689036
Drug: 3g edetate
RxNorm normalized name: EDETATE
DrugBank: Edetate sodium (DB13404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3g edetate disodium-based infusion
Trial: 28689036
Drug: Placebo infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infusion of 500mL normal saline and 1.2% dextrose
Trial: 21107585
Drug: Group-based treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group-based treatment (GT)
Trial: 20957391
Drug: Individual treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual treatment (IT)
Trial: 22253980
Drug: Bovine colostrum
RxNorm normalized name: Bovine Colostrum
DrugBank: Bos taurus colostrum (DB19249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bovine colostrum (BC) supplementation (60 g/day)
Trial: 17427144
Drug: Influenza split
RxNorm normalized name: INFLUENZA SPLIT VIRUS '95-'96 VIL 5ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Influenza split vaccine vaccination
Trial: 11221809
Drug: Bedtime NPH
RxNorm normalized name: Buckley's Bedtime Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bedtime NPH insulin
Trial: 8365296
Drug: Endotoxin (7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endotoxin (7 mg/L)
Trial: 8365296
Drug: Corn dust
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corn dust extract (0.08 ml/kg)
Trial: 8365296
Drug: Soybean dust
RxNorm normalized name: Soybean dust
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soybean dust extract (0.08 ml/kg)
Trial: 25626910
Drug: Pars plana
RxNorm normalized name: Planatus occidentalis bark extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pars plana vitrectomy and 360° endolaser therapy
Trial: 18412565
Drug: 8% Aluminium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8% Aluminium Chlorohydrate (ACH) aqueous solution
Trial: 18412565
Drug: 4%, 8%,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4%, 8%, or 12% Aluminium Chlorohydrate (ACH) aqueous solution
Trial: 12494207
Drug: Telmisartan (40‐80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan (40‐80 mg/day) for 24 weeks
Trial: 7877305
Drug: Acadesine (low-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acadesine (low-dose and high-dose)
Trial: 2212216
Drug: Metronidazole (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole (250 mg, three times a day for one week) with scaling and root planing
Trial: 355807
Drug: Sublingual milk
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual milk therapy
Trial: 30359166
Drug: Adjunctive ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adjunctive ondansetron (8 mg/daily)
Trial: 17579629
Drug: Carboplatin plus
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin plus etoposide (CE); carboplatin AUC 5 IV on day 1 and etoposide 80 mg/m² IV on days 1-3, with G-CSF support for 4 courses.
Trial: 17579629
Drug: Split doses
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Split doses of cisplatin plus etoposide (SPE); cisplatin 25 mg/m² IV on days 1-3 and etoposide 80 mg/m² IV on days 1-3, with G-CSF support for 4 courses.
Trial: 17579629
Drug: Split doses
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Split doses of cisplatin plus etoposide (SPE)
Trial: 16100444
Drug: FPG <5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FPG <5.0 mM/L (Group 1)
Trial: 16100444
Drug: 5.6< or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.6< or =FPG <6.1 mM/L (Group 3)
Trial: 16100444
Drug: 6.1< or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6.1< or =FPG <7.0 mM/L (Group 4)
Trial: 12085177
Drug: Marimastat (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marimastat (10 mg b.d.)
Trial: 8903664
Drug: Mibefradil 150
RxNorm normalized name: mibefradil
DrugBank: Mibefradil (DB01388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mibefradil 150 mg (acute study)
Trial: 8903664
Drug: Verapamil SR
RxNorm normalized name: Dom-Verapamil SR
DrugBank: Verapamil (DB00661)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Verapamil SR 240 mg (acute study)
Trial: 8903664
Drug: Diltiazem 240
RxNorm normalized name: diltiazem 240 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem 240 mg (acute study)
Trial: 8903664
Drug: Mibefradil 100
RxNorm normalized name: mibefradil 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mibefradil 100 mg daily (chronic study)
Trial: 8903664
Drug: Verapamil SR
RxNorm normalized name: Dom-Verapamil SR
DrugBank: Verapamil (DB00661)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Verapamil SR 240 mg daily (chronic study)
Trial: 2295997
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of fluoride mouthrinsing and fluoride tablets
Trial: 2295997
Drug: Fluoride tablets
RxNorm normalized name: Sodium Fluoride Tablets
DrugBank: Sodium fluorophosphate (DB09484)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoride tablets (2.2 mg NaF daily)
Trial: 2295997
Drug: Fluoride mouthrinsing
RxNorm normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoride mouthrinsing (0.2% NaF solution weekly)
Trial: 271588
Drug: Sodium fluoride
RxNorm normalized name: Sodium Fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium fluoride jelly (four times continuous daily application)
Trial: 271588
Drug: Aminofluoride jelly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminofluoride jelly (four times continuous daily application)
Trial: 31068298
Drug: 1 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 μg/kg sufentanil combined with TAP block
Trial: 31068298
Drug: 2 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 μg/kg sufentanil without TAP block
Trial: 19707744
Drug: Insulin detemir
RxNorm normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Insulin detemir (0.5 U/kg body weight)
Trial: 19707744
Drug: NPH insulin
RxNorm normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPH insulin (0.5 U/kg body weight)
Trial: 19707744
Drug: Both insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Both insulin detemir and NPH insulin
Trial: 18158020
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg BCG
Trial: 18158020
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg BCG
Trial: 18158020
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg BCG
Trial: 12357261
Drug: Implantable cardioverter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implantable cardioverter defibrillator and radiofrequency ablation in addition to antiarrhythmic drugs
Trial: 10027342
Drug: Dexamethasone 20
RxNorm normalized name: dexamethasone 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 20 mg with 5-HT3 antagonists
Trial: 10027342
Drug: Dexamethasone 8
RxNorm normalized name: dexamethasone 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 8 mg with 5-HT3 antagonists
Trial: 10027342
Drug: Medium-dose dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Medium-dose dexamethasone (8 mg) with 5-HT3 antagonists
Trial: 6357659
Drug: Indomethacin 50
RxNorm normalized name: indomethacin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin 50 mg taken at 1200
Trial: 31905228
Drug: Typhax 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Typhax 0.5 μg
Trial: 31905228
Drug: Typhax 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Typhax 2.5 μg
Trial: 31905228
Drug: Typhax 10
RxNorm normalized name: TYPHA ANGUSTIFOLIA STEM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Typhax 10 μg
Trial: 31905228
Drug: Typhim Vi
RxNorm normalized name: Typhim VI
DrugBank: Typhoid Vi polysaccharide vaccine (DB10803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Typhim Vi (25 μg)
Trial: 27101283
Drug: IncobotulinumtoxinA injections
RxNorm normalized name: incobotulinumtoxinA Injection
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: IncobotulinumtoxinA injections at weeks 0, 16, and 32
Trial: 27101283
Drug: IncobotulinumtoxinA injections
RxNorm normalized name: incobotulinumtoxinA Injection
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: IncobotulinumtoxinA injections
Trial: 22198448
Drug: Asenapine 5
RxNorm normalized name: asenapine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asenapine 5 or 10 mg
Trial: 20958294
Drug: OnabotulinumtoxinA injection
RxNorm normalized name: onabotulinumtoxinA Injection
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: OnabotulinumtoxinA injection using the PREEMPT paradigm (both fixed and follow-the-pain sites)
Trial: 30346346
Drug: OnabotulinumtoxinA injection
RxNorm normalized name: onabotulinumtoxinA Injection
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: OnabotulinumtoxinA injection
Trial: 10605180
Drug: Cetrorelix 60
RxNorm normalized name: Cetrorelix
DrugBank: Cetrorelix (DB00050)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cetrorelix 60 mg
Trial: 27062408
Drug: Fenofibrate 100
RxNorm normalized name: fenofibrate 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibrate 100 mg QD
Trial: 30193843
Drug: DHEA administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA administration (100 mg/day for 4 weeks)
Trial: 27072219
Drug: Accelerated radiotherapy
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated radiotherapy (ART) - 50 Gy in 25 fractions, six fractions weekly